Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia (BEACON)

Otsuka

Status and phase: Completed; Phase 3

Conditions: Acute Schizophrenia

Treatments: Drug: OPC-34712; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01393613

331-10-230

Details and patient eligibility

About

The purpose of this study is to assess the efficacy, safety, and tolerability of fixed doses of OPC-34712 versus placebo for the treatment of adult subjects with an acute relapse of schizophrenia.

Full description

Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the world population. Hallucinations and delusions are the most striking characteristic positive symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and lack of emotion, energy, and motivation) may also be present. The first antipsychotics developed for the treatment of schizophrenia were effective against positive symptoms, but showed little efficacy for negative symptoms and were also associated with a high incidence of side effects. Second generation antipsychotics, represent a significant advancement in the treatment of psychotic disorders because they are effective and at the same time exhibit fewer side effects than first generation antipsychotics. Although generally safer than first generation antipsychotics, the second-generation antipsychotics are not devoid of undesirable side effects such as Hyperprolactinemia and weight gain. In addition, the safety of these drugs vary considerably.

Enrollment: 674 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by DSM-IV-TR criteria
2. Subjects who have been recently hospitalized or who would benefit from hospitalization for an acute relapse of schizophrenia
3. Subjects experiencing an acute exacerbation of psychotic symptoms
4. Other protocol specific inclusion criteria may apply

Exclusion criteria

1. Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug

2. Subjects with a current DSM-IV-TR Axis I diagnosis of:

   • Schizoaffective disorder
   • MDD
   • Bipolar disorder
   • Delirium, dementia, amnestic or other cognitive disorder
   • Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder

3. Subjects presenting with a first episode of schizophrenia

4. Other protocol specific exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

674 participants in 4 patient groups, including a placebo group

Dose 3 OPC 34712

Experimental group

Description:

Higher dose, tablet, once daily, for six weeks

Treatment:

Drug: OPC-34712

Drug: OPC-34712

Drug: OPC-34712

Dose 2 OPC 34712

Experimental group

Description:

Middle dose, tablet, once daily, for six weeks

Treatment:

Drug: OPC-34712

Drug: OPC-34712

Drug: OPC-34712

Dose 1 OPC 34712

Experimental group

Description:

Lower dose, tablet, once daily, for six weeks

Treatment:

Drug: OPC-34712

Drug: OPC-34712

Drug: OPC-34712

Placebo

Placebo Comparator group

Description:

Placebo, once daily, for six weeks

Treatment:

Drug: Placebo